The recent ruling by a U.S. court allowing scientific evidence to be presented in lawsuits related to the discontinued heartburn drug Zantac has sent shockwaves through the pharmaceutical industry. British pharmaceuticals giant GSK saw its shares plummet by 9% after the ruling, highlighting the potential financial implications for the company and others involved in the